A comparative prospective open label randomized controlled 8 week study in patients of depression treated with vilazodone and sertraline

Simple item page
dc.contributor.authorArya, Nirmalen_US
dc.contributor.authorNischal, Anuradhaen_US
dc.contributor.authorNischal, Anilen_US
dc.contributor.authorAgarwal, Manuen_US
dc.date.accessioned2020-04-09T07:43:57Z
dc.date.available2020-04-09T07:43:57Z
dc.date.issued2020-04
dc.description.abstractBackground: Depression is a mood disorder treated with various antidepressant such as SSRIs due to lesser toxicity and improved safety profile.Methods: This was an eight week randomised active controlled parallel group study. 54 patients were allocated in two group. Group A received vilazodone while group B received sertraline. Assessment done at baseline, 2, 4 and 8 weeks on the basis of clinical efficacy, sexual dysfunction, side effects and weight gain using Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), Arizona Sexual Experience Scale (ASEX) and UKU Side Effect Rating Scale.Results: HAM-D score of group A was 18.78±1.78 and 7.67±1.66 while in group B was 19.04±2.12 and 8.15±1.77 at baseline and 8 weeks respectively. HAM-A score of group A was 15.44±1.50 and 6.63±1.39 while in group B was 15.26±1.83 and 7.07±1.14 at baseline and 8 weeks. ASEX total score of group A was 15.63±1.28 and 14.63±1.33 while group B was 15.52±1.37 and 16.41±1.12 at baseline and 8 weeks. ASEX desire score of group A was 9.63±0.93 and 8.67±0.88 while of group B was 9.59±0.93 and 10.07±0.92 at baseline and 8 weeks. UKU side effect rating at 2 and 8 weeks of group A was 0.22±0.42, 1.04±0.76 while in group B was 0.37±0.49, 1.89±0.85.Conclusions: Vilazodone and Sertraline are equally efficacious in treatment of depression and associated anxiety. When side effect profile were compared Vilazodone is found superior to Sertralineen_US
dc.identifier.affiliationsDepartment of Medicine, JNMC, AMU Aligarh, Uttar Pradesh, Indiaen_US
dc.identifier.citationArya Nirmal, Nischal Anuradha, Nischal Anil, Agarwal Manu. A comparative prospective open label randomized controlled 8 week study in patients of depression treated with vilazodone and sertraline. International Journal of Advances in Medicine. 2020 Apr; 7(4): 643-649en_US
dc.identifier.issn2349-3925
dc.identifier.issn2349-3933
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/194654
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber4en_US
dc.relation.volume7en_US
dc.source.urihttps://dx.doi.org/10.18203/2349-3933.ijam20201115en_US
dc.subjectAnxietyen_US
dc.subjectDepressionen_US
dc.subjectSertralineen_US
dc.subjectSexual dysfunctionen_US
dc.subjectVilazodoneen_US
dc.titleA comparative prospective open label randomized controlled 8 week study in patients of depression treated with vilazodone and sertralineen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijam2020v7n4p643.pdf
Size:
271.65 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Advances in Medicine